Paper · 42591661
FGFR1 copy number gain is independently associated with shorter progression-free survival in advanced lung squamous cell carcinoma treated with first-line immune checkpoint inhibitor-based therapy.
Mu S and 3 others. Front Immunol, 2026. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. FGFR1 copy number gain is independently associated with shorter progression-free survival in advanced lung squamous cell carcinoma treated with first-line immune checkpoint inhibitor-based therapy. Papers, record 42591661. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42591661
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- FGFR1 copy number gain is independently associated with shorter progression-free survival in advanced lung squamous cell carcinoma treated with first-line immune checkpoint inhibitor-based therapy.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptor, Fibroblast Growth Factor, Type 1 | Major topic |
| Lung Neoplasms | Major topic |
| Immune Checkpoint Inhibitors | Major topic |
| DNA Copy Number Variations | Major topic |
| Carcinoma, Squamous Cell | Major topic |
| Humans | |
| Female | |
| Male | |
| Retrospective Studies | |
| Progression-Free Survival | |
| Middle Aged | |
| Aged | |
| Prognosis | |
| Biomarkers, Tumor | |
| Neoplasm Staging | |
| Gene Dosage |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36,966,334 | Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment. | Mol Cancer | 2023 | https://conductscience.org/library/papers/36966334 | PubMed |
| 2 | 22,722,794 | Genetic changes in squamous cell lung cancer: a review. | J Thorac Oncol | 2012 | https://conductscience.org/library/papers/22722794 | PubMed |
| 3 | 40,140,911 | Recent advances in therapeutic strategies for non-small cell lung cancer. | J Hematol Oncol | 2025 | https://conductscience.org/library/papers/40140911 | PubMed |
| 4 | 30,820,185 | Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer. | J Med Biochem | 2019 | https://conductscience.org/library/papers/30820185 | PubMed |
| 5 | 41,712,875 | Current Insights and Future Directions of Multiomic and Spatial-Omic Analysis in Non-Small Cell Lung Cancer. | JCO Precis Oncol | 2026 | https://conductscience.org/library/papers/41712875 | PubMed |
| 6 | 20,094,046 | Fibroblast growth factor signalling: from development to cancer. | Nat Rev Cancer | 2010 | https://conductscience.org/library/papers/20094046 | PubMed |
| 7 | 37,600,482 | Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials. | EClinicalMedicine | 2023 | https://conductscience.org/library/papers/37600482 | PubMed |
| 8 | 35,008,273 | Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/35008273 | PubMed |
| 9 | 41,514,604 | FGFR Aberrations in Solid Tumors: Mechanistic Insights and Clinical Translation of Targeted Therapies. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41514604 | PubMed |
| 10 | 39,544,292 | Landscape of targeted therapies for lung squamous cell carcinoma. | Front Oncol | 2024 | https://conductscience.org/library/papers/39544292 | PubMed |
1 to 10 of 41
See all 41 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
None in this release.
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29,126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| FGFR1 | 2,260 | PubTator's text mining | https://conductscience.org/library/genes/2260 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42591661
GET https://conductscience.org/api/papers/v1/42591661/references?page=2